Cargando…

Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic

BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sansom, Sarah E, Martin, Jonathan, Adeyemi, Oluwatoyin, Burke, Kerianne, Winston, Crystal, Markham, Sara, Go, Benjamin, Huhn, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451651/
https://www.ncbi.nlm.nih.gov/pubmed/30968054
http://dx.doi.org/10.1093/ofid/ofz099
_version_ 1783409196424757248
author Sansom, Sarah E
Martin, Jonathan
Adeyemi, Oluwatoyin
Burke, Kerianne
Winston, Crystal
Markham, Sara
Go, Benjamin
Huhn, Gregory
author_facet Sansom, Sarah E
Martin, Jonathan
Adeyemi, Oluwatoyin
Burke, Kerianne
Winston, Crystal
Markham, Sara
Go, Benjamin
Huhn, Gregory
author_sort Sansom, Sarah E
collection PubMed
description BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, which may limit recognition of steatosis. We evaluated steatosis rates by LB and transient elastography (TE) with controlled attenuation parameter (CAP) among HCV-infected and HIV/HCV-coinfected patients in a US clinic. METHODS: Patients with chronic HCV infection during pretreatment evaluation by LB (n = 421; December 2001 through May 2014) and TE with CAP (n = 1157; May 2016 through May 2017) were included. Fibrosis and steatosis rates by LB and TE with CAP were stratified by HCV versus HIV/HCV coinfection status. RESULTS: Steatosis was not reported in 26.1% of LBs. Moderate to severe steatosis (grade ≥S2) was detected more often with CAP than with LB (in 24.0% vs 11.4% of patients, respectively). Median CAP values were higher in patients with HCV monoinfection than in those with coinfection (230 vs 215.5 dB/m, respectively; P < .001). With TE, the rate of advanced fibrosis (values F3–F4) was higher in HCV monoinfection than in coinfection (25.9% vs 14.8%, respectively; P <.001). With both LB and TE, advanced fibrosis (F3–F4) was significantly associated with moderate to severe steatosis (S2–S3) in HCV monoinfection compared with HIV/HCV coinfection (33.3% vs 4.4%, respectively for LB [P = 0.003] and 36.0% vs 29.0% for TE [P = 0.008]). CONCLUSIONS: In patients with chronic HCV undergoing liver fibrosis staging, steatosis was detected more often with CAP than LB, with median CAP values higher in HCV monoinfection than HIV/HCV coinfection. Steatosis severity may be increasing in the modern HCV treatment era.
format Online
Article
Text
id pubmed-6451651
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64516512019-04-09 Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic Sansom, Sarah E Martin, Jonathan Adeyemi, Oluwatoyin Burke, Kerianne Winston, Crystal Markham, Sara Go, Benjamin Huhn, Gregory Open Forum Infect Dis Major Article BACKGROUND: Steatosis contributes to liver fibrosis in hepatitis C virus (HCV) and human immunodeficiency virus (HIV)/HCV coinfection. Liver biopsy (LB) is the reference standard for grading steatosis and staging fibrosis, yet recent advances in noninvasive modalities have largely supplanted LB, which may limit recognition of steatosis. We evaluated steatosis rates by LB and transient elastography (TE) with controlled attenuation parameter (CAP) among HCV-infected and HIV/HCV-coinfected patients in a US clinic. METHODS: Patients with chronic HCV infection during pretreatment evaluation by LB (n = 421; December 2001 through May 2014) and TE with CAP (n = 1157; May 2016 through May 2017) were included. Fibrosis and steatosis rates by LB and TE with CAP were stratified by HCV versus HIV/HCV coinfection status. RESULTS: Steatosis was not reported in 26.1% of LBs. Moderate to severe steatosis (grade ≥S2) was detected more often with CAP than with LB (in 24.0% vs 11.4% of patients, respectively). Median CAP values were higher in patients with HCV monoinfection than in those with coinfection (230 vs 215.5 dB/m, respectively; P < .001). With TE, the rate of advanced fibrosis (values F3–F4) was higher in HCV monoinfection than in coinfection (25.9% vs 14.8%, respectively; P <.001). With both LB and TE, advanced fibrosis (F3–F4) was significantly associated with moderate to severe steatosis (S2–S3) in HCV monoinfection compared with HIV/HCV coinfection (33.3% vs 4.4%, respectively for LB [P = 0.003] and 36.0% vs 29.0% for TE [P = 0.008]). CONCLUSIONS: In patients with chronic HCV undergoing liver fibrosis staging, steatosis was detected more often with CAP than LB, with median CAP values higher in HCV monoinfection than HIV/HCV coinfection. Steatosis severity may be increasing in the modern HCV treatment era. Oxford University Press 2019-03-01 /pmc/articles/PMC6451651/ /pubmed/30968054 http://dx.doi.org/10.1093/ofid/ofz099 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Sansom, Sarah E
Martin, Jonathan
Adeyemi, Oluwatoyin
Burke, Kerianne
Winston, Crystal
Markham, Sara
Go, Benjamin
Huhn, Gregory
Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title_full Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title_fullStr Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title_full_unstemmed Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title_short Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic
title_sort steatosis rates by liver biopsy and transient elastography with controlled attenuation parameter in clinical experience of hepatitis c virus (hcv) and human immunodeficiency virus/hcv coinfection in a large us hepatitis clinic
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451651/
https://www.ncbi.nlm.nih.gov/pubmed/30968054
http://dx.doi.org/10.1093/ofid/ofz099
work_keys_str_mv AT sansomsarahe steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT martinjonathan steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT adeyemioluwatoyin steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT burkekerianne steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT winstoncrystal steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT markhamsara steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT gobenjamin steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic
AT huhngregory steatosisratesbyliverbiopsyandtransientelastographywithcontrolledattenuationparameterinclinicalexperienceofhepatitiscvirushcvandhumanimmunodeficiencyvirushcvcoinfectioninalargeushepatitisclinic